Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 17/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.77 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2878377 | 1.00 | OPRL1 (0.77) | OPRL1KCNH2SIGMAR1DRD2DRD4 | |
| SCHEMBL2880928 | 1.00 | OPRL1 (0.77) | OPRL1KCNH2SIGMAR1DRD2DRD4 | |
| SCHEMBL2883922 | 0.87 | OPRL1 (0.79) | OPRL1KCNH2SIGMAR1 | |
| SCHEMBL2877459 | 0.87 | OPRL1 (0.79) | OPRL1KCNH2SIGMAR1 | |
| SCHEMBL2877461 | 0.87 | OPRL1 (0.79) | OPRL1KCNH2SIGMAR1 | |
| SCHEMBL2882370 | 0.87 | OPRL1 (1.00) | OPRL1KCNH2 | |
| SCHEMBL2882367 | 0.87 | OPRL1 (1.00) | OPRL1KCNH2 | |
| SCHEMBL2885269 | 0.87 | OPRL1 (1.00) | OPRL1KCNH2 | |
| SCHEMBL2882533 | 0.79 | OPRL1 (0.85) | OPRL1KCNH2 | |
| SCHEMBL2882854 | 0.79 | OPRL1 (0.85) | OPRL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | claimed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | claimed |
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | OPRL1 1/4885KCNH2 969/4885SIGMAR1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.